Further it needs to be evaluated whether the hyporesponsive phenotypical state of CLL-patient derived NK cells is revertible or if allogeneic NK cell therapy could benefit from selective targeting of the AR (47), possibly in combination with other immunomodulatory drugs (44, 80, 81). Here, AR is linked to B-cell chronic lymphocytic leukemia.